ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months — but have fewer side effec
ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months — but have fewer side effects — according to study findings announced at the 2013 ASCO Genitourinary Cancers Symposium in Orlando. Dr Abdenour Nabid from Sherbrooke University in Quebec gave Peter Goodwin the details.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/130310AbdenourNabidAJOPODCASTLoRes.mp3]